Rafael Holdings develops novel cancer and immune therapies through strategic investments in clinical-stage oncology companies, focusing on therapeutic assets that target high unmet medical needs. The company aims to improve patient outcomes and extend survival rates by advancing innovative treatments in oncology.
Funding
$104.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers lack effective treatments, resulting in high unmet medical needs and poor patient outcomes. Traditional approaches may not adequately target specific cancer vulnerabilities or stimulate the immune system to fight the disease.
Solution
Rafael Holdings invests in and develops novel cancer and immune therapies focused on addressing unmet medical needs in oncology. The company strategically invests in clinical-stage oncology companies with therapeutic assets that target specific cancer vulnerabilities and stimulate the immune system. By advancing innovative treatments, Rafael Holdings aims to improve patient outcomes and extend survival rates in various cancer types.
Target Audience
The primary target audience includes patients with cancer, oncologists, and the broader medical community seeking innovative treatment options.
Features
- Investment in clinical-stage oncology companies.
- Focus on therapeutic assets targeting high unmet medical needs.
- Development of novel cancer and immune therapies.
- Aims to improve patient outcomes and extend survival rates.